INCY Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$127.12median target· current $127.98 (-0.7%)27 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
30 articles · sorted by datePage 1 of 2 · 30 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio16.28Forward 41.67
EPS (TTM)$7.8637.7% YoY
Profit margin27.7%HEALTHCARE
Market cap$25.94BLarge cap
Valuation
- Forward P/E
- 41.67
- PEG ratio
- 30.83
- P/B
- 4.08
- P/S (TTM)
- 4.46
- EV/EBITDA
- 10.35
Profitability & growth
- ROE (TTM)
- 30.7%
- Operating margin
- 41.9%
- Revenue growth YoY
- 37.7%
- Dividend yield
- —
- Beta
- 0.77
Last earnings
Jul 28, 2026 · Estimate $1.76 · Reported $2.80
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Incyte Corporation
Company profileIncyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$25.94B
Shares outstanding$202.7M
52W high$132.60
52W low$81.09
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent